Home slider beeld 02
Lab website TS Essen.jpg
myeuniter_gruppenfoto-8234_beschriftet borderless web.jpg

    In cancer, infection and inflammation, the immune system’s function is dysregulated, contributing to disease pathology. As part of this process, instead of fighting disease, immune cells may even suppress beneficial immune responses and increase pathology. Despite their pathophysiological importance, the identity and biology of the so called myeloid regulatory cells (MRCs) is poorly understood.


    European Task Force on Myeloid Regulatory Cells:


    Myeloid Regulatory Cells: Novel Players in Cancer Immunotherapy:


    European Network of Investigators Triggering Exploratory Research on Myeloid Regulatory Cells


    Action Chair: Sven Brandau (DE)

    Vice-Chair: Annabel Valledor (ES)

    News and Events
    There is no news at the moment
    There are no events at the moment

    This COST Action officially ended on 26 November 2018


    The COST Action Mye-EUNITER is proud to announce the completion of a Symposium-in-Writing in Cancer Immunology Immunotherapy which has been written by its members:

    Editorial: MDSC and beyond: a symposium-in-writing on myeloid cells with immunoregulatory activity by members of the Mye-EUNITER network. Brandau S. Cancer Immunol Immunother. 2019 Mar 18. doi: 10.1007/s00262-019-02325-9

    Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates. Cassetta L, Baekkevold ES, Brandau S, Bujko A, Cassatella MA, Dorhoi A, Krieg C, Lin A, Loré K, Marini O, Pollard JW, Roussel M, Scapini P, Umansky V, Adema GJ. Cancer Immunol Immunother. 2019 Jan 25. doi: 10.1007/s00262-019-02302-2

    MDSCs in infectious diseases: regulation, roles, and readjustment. Dorhoi A, Glaría E, Garcia-Tellez T, Nieuwenhuizen NE, Zelinskyy G, Favier B, Singh A, Ehrchen J, Gujer C, Münz C, Saraiva M, Sohrabi Y, Sousa AE, Delputte P, Müller-Trutwin M, Valledor AF. Cancer Immunol Immunother. 2018 Dec 19. doi: 10.1007/s00262-018-2277-y

    Role of myeloid regulatory cells (MRCs) in maintaining tissue homeostasis and promoting tolerance in autoimmunity, inflammatory disease and transplantation. Amodio G, Cichy J, Conde P, Matteoli G, Moreau A, Ochando J, Oral BH, Pekarova M, Ryan EJ, Roth J, Sohrabi Y, Cuturi MC, Gregori S. Cancer Immunol Immunother. 2018 Oct 24. doi: 10.1007/s00262-018-2264-3

    Interactions among myeloid regulatory cells in cancer. Umansky V, Adema GJ, Baran 4, Brandau S, Van Ginderachter JA, Hu X, Jablonska J, Mojsilovic S, Papadaki HA, Pico de Coaña Y, Santegoets KCM, Santibanez JF, Serre K, Si Y, Sieminska I, Velegraki M, Fridlender ZG. Cancer Immunol Immunother. 2018 Jul 12. doi: 10.1007/s00262-018-2200-6

    How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions. Bruger AM, Dorhoi A, Esendagli G, Barczyk-Kahlert K, van der Bruggen P, Lipoldova M, Perecko T, Santibanez J, Saraiva M, Van Ginderachter JA, Brandau S. Cancer Immunol Immunother. 2018 May 21. doi: 10.1007/s00262-018-2170-8

    © Springer-Verlag GmbH Germany, part of Springer Nature 2018

    Myeloid-Derived Suppressor Cells in Hematologic Diseases. Promising Biomarkers and Treatment Targets. Bizymi N, Bjelica S, Kittang AO, Mojsilovic S, Velegraki M, Pontikoglou C, Roussel M, Ersvær E, Santibañez JF, Lipoldová M, Papadaki H. HemaSphere, 2019;3:1. doi: 10.1097/HS9.0000000000000168.

    © Wolters Kluwer Health, Inc. HemaSphere, the open access Journal of the European Hematology Association, 2019

    Cancer II.jpg